ONCY

Oncolytics Biotech Inc.

Price Chart

Latest Quote

$0.92

-0.04 (-4.46%)

Current Price

Previous Close	$0.96
Open	$0.99
Day High	$1.02
Day Low	$0.91
Volume	1,034,752

Fetched: 2026-06-23T12:22:17

Stock Information

Shares Outstanding	119.35M
Total Debt	$508K
Cash Equivalents	$5.49M
Net Income	$-33.29M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$109.47M
EPS (TTM)	$-0.32
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$104.49M
Income	$-33.29M
Book/sh	$-0.04
Cash/sh	$0.05
Employees	29

Financial Ratios

Quick Ratio	1.19
Current Ratio	1.38

Returns & Margins

ROA

-188.55%

Ownership

Insider Ownership	2.19%
Institutional Ownership	3.24%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-3.88
P/B	-20.85

Analyst Data

Recommendation	buy
Target Price	$4.93

Technical Indicators

SMA20	$0.89
SMA50	$0.92
SMA200	$1.03
RSI	37.04
ATR	0.0764

Shares Float	116.88M
Short Float	5.90%
Short Ratio	6.42
Volatility	1.08
Rel Volume	0.58

Performance History

Week	+15.00%
Month	+12.20%
Quarter	-3.16%
6 Months	-8.91%
YTD	-6.12%
Year	+24.32%
3 Years	-52.33%
5 Years	-68.38%
10 Years	-74.52%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-22	$0.92	1,035,900
2026-06-18	$0.96	1,129,400
2026-06-17	$0.93	1,686,400
2026-06-16	$0.95	2,637,400
2026-06-15	$0.85	1,162,200
2026-06-12	$0.80	649,600
2026-06-11	$0.82	1,673,700
2026-06-10	$0.80	2,070,800
2026-06-09	$0.81	2,056,700
2026-06-08	$0.84	1,180,800
2026-06-05	$0.84	1,052,600
2026-06-04	$0.87	1,019,900
2026-06-03	$0.88	1,559,500
2026-06-02	$0.93	2,814,000
2026-06-01	$1.06	6,403,100
2026-05-29	$1.04	2,878,800
2026-05-28	$0.94	1,998,600
2026-05-27	$0.90	1,654,400
2026-05-26	$0.81	495,000

About Oncolytics Biotech Inc.

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.

📰 Latest News

Sector Update: Healthcare Stocks Advance in Afternoon Trading

MT Newswires • 2026-06-16T17:29:11Z

ONCY Stock Surged Today – Here’s What Securing A Key Immunotherapy Patent Means For Oncolytics

Stocktwits • 2026-06-16T16:42:26Z

Oncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor Attention

Simply Wall St. • 2026-06-04T06:11:21Z

ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study

Stocktwits • 2026-06-01T15:26:07Z

Oncolytics Biotech Reports Data in Colorectal Cancer Study

IPO-Edge.com • 2026-05-06T22:48:07Z

Oncolytics Biotech’s Nevada Move Resets Capital Access And Dilution Trade Off

Simply Wall St. • 2026-04-01T20:07:09Z

Assessing Oncolytics Biotech (ONCY) Valuation After FDA Fast Track Designation For Pelareorep

Simply Wall St. • 2026-02-16T13:12:19Z

Why Oncolytics Biotech (ONCY) Is Up 19.7% After FDA Fast Track For KRAS-Mutant Colorectal Cancer

Simply Wall St. • 2026-02-15T11:13:28Z

Oncolytics receives FDA Fast Track Designation for pelareorep

TipRanks • 2026-02-05T13:55:27Z

Oncolytics Biotech (ONCY) Leadership Strengthens As Pelareorep Advances

Insider Monkey • 2026-01-12T09:23:50Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$28,725,000	$25,542,000	$25,471,883	$19,837,902
Other Income Expense	$-341,000	$1,868,000	$3,625,810	$1,212,054
Other Non Operating Income Expenses	$-388,000	-	-	-
Net Non Operating Interest Income Expense	$386,000	$975,000	$999,548	$389,036
Operating Expense	$28,725,000	$25,542,000	$25,471,883	$19,837,902
General And Administrative Expense	$15,411,000	$10,099,000	$11,818,936	$8,178,603
Other Operating Expenses	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-28,759,000	$-22,794,000	$-20,919,644	$-18,298,703
Net Interest Income	$386,000	$975,000	$999,548	$389,036
Interest Income	$386,000	$975,000	$999,548	$389,036
Normalized Income	$-28,796,130	$-24,269,720	$-23,784,034	$-19,256,226
Net Income From Continuing And Discontinued Operation	$-28,759,000	$-22,794,000	$-20,919,644	$-18,298,703
Total Operating Income As Reported	$-28,725,000	$-25,542,000	-	-
Net Income Common Stockholders	$-28,759,000	$-22,794,000	$-20,919,644	$-18,298,703
Net Income	$-28,759,000	$-22,794,000	$-20,919,644	$-18,298,703
Net Income Including Noncontrolling Interests	$-28,759,000	$-22,794,000	$-20,919,644	$-18,298,703
Net Income Continuous Operations	$-28,759,000	$-22,794,000	$-20,919,644	$-18,298,703
Pretax Income	$-28,680,000	$-22,699,000	$-20,846,525	$-18,236,811
Interest Income Non Operating	$386,000	$975,000	$999,548	$389,036
Operating Income	$-28,725,000	$-25,542,000	$-25,471,883	$-19,837,902
Depreciation Amortization Depletion Income Statement	-	$295,431	$303,784	$288,830
Depreciation And Amortization In Income Statement	-	$295,431	$303,784	$288,830
Depreciation Income Statement	-	$295,431	$303,784	$288,830
Per Share
Diluted EPS	$-0.30	$-0.29	$-0.31	$-0.32
Basic EPS	$-0.30	$-0.29	$-0.31	$-0.32
Other
Tax Effect Of Unusual Items	$9,870	$392,280	$761,420	$254,531
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-28,702,000	$-27,323,000	$-28,793,909	$-20,761,126
Total Unusual Items	$47,000	$1,868,000	$3,625,810	$1,212,054
Total Unusual Items Excluding Goodwill	$47,000	$1,868,000	$3,625,810	$1,212,054
Reconciled Depreciation	$70,000	$87,000	$303,784	$288,830
EBITDA (Bullshit earnings)	$-28,655,000	$-25,455,000	$-25,168,099	$-19,549,072
EBIT	$-28,725,000	$-25,542,000	$-25,471,883	$-19,837,902
Diluted Average Shares	$95,857,147	$76,482,914	$67,624,036	$58,029,745
Basic Average Shares	$95,857,147	$76,482,914	$67,624,036	$58,029,745
Diluted NI Availto Com Stockholders	$-28,759,000	$-22,794,000	$-20,919,644	$-18,298,703
Tax Provision	$79,000	$95,000	$73,119	$61,892
Gain On Sale Of Security	$47,000	$1,868,000	$3,625,810	$1,212,054
Research And Development	$13,314,000	$15,443,000	$13,349,163	$11,370,469
Selling General And Administration	$15,411,000	$10,099,000	$11,818,936	$8,178,603
Other Gand A	$11,550,000	$6,692,000	$8,845,922	$5,321,986
Salaries And Wages	$3,861,000	$3,407,000	$2,973,014	$2,856,617

Fetched: 2026-06-18

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$-3,799,000	$3,298,000	$20,777,175	$19,526,967
Total Assets	$7,582,000	$13,421,000	$29,262,777	$27,508,105
Total Non Current Assets	$738,000	$985,000	$487,713	$1,215,738
Current Assets	$6,844,000	$12,436,000	$28,775,064	$26,292,367
Prepaid Assets	$1,069,000	$1,310,000	$2,446,857	$2,228,854
Receivables	$573,000	$47,000	$11,307	$383,879
Other Receivables	$573,000	$47,000	$11,307	$383,879
Cash Cash Equivalents And Short Term Investments	$5,202,000	$11,079,000	$26,316,900	$23,679,635
Cash And Cash Equivalents	$5,202,000	$11,079,000	$26,316,900	$8,595,638
Hedging Assets Current	-	$980,000	$0	-
Non Current Prepaid Assets	-	-	$0	$735,337
Debt
Total Debt	$563,000	$761,000	$318,860	$274,831
Long Term Debt And Capital Lease Obligation	$370,000	$561,000	$218,604	$115,679
Current Debt And Capital Lease Obligation	$193,000	$200,000	$100,256	$159,151
Liabilities
Total Liabilities Net Minority Interest	$11,381,000	$10,123,000	$8,485,602	$7,981,138
Total Non Current Liabilities Net Minority Interest	$5,280,000	$5,238,000	$5,291,723	$5,074,418
Non Current Deferred Liabilities	$4,910,000	$4,677,000	$5,073,119	$4,958,739
Current Liabilities	$6,101,000	$4,885,000	$3,193,879	$2,906,720
Other Current Liabilities	$77,000	$1,355,000	$401,025	$58,208
Payables And Accrued Expenses	$5,831,000	$3,330,000	$2,692,598	$2,689,360
Payables	$3,504,000	$756,000	$815,619	$1,659,299
Accounts Payable	$3,504,000	$756,000	$815,619	$1,659,299
Equity
Common Stock Equity	$-3,799,000	$3,298,000	$20,777,175	$19,526,967
Total Equity Gross Minority Interest	$-3,799,000	$3,298,000	$20,777,175	$19,526,967
Stockholders Equity	$-3,799,000	$3,298,000	$20,777,175	$19,526,967
Gains Losses Not Affecting Retained Earnings	$6,225,000	$6,361,000	$410,071	$487,769
Other Equity Adjustments	$6,225,000	$6,361,000	$410,071	$487,769
Retained Earnings	$-429,495,000	$-400,736,000	$-336,200,060	$-308,171,972
Other Equity Interest	-	-	-	-
Other
Ordinary Shares Number	$108,021,271	$80,020,131	$74,423,960	$61,327,914
Share Issued	$108,021,271	$80,020,131	$74,423,960	$61,327,914
Tangible Book Value	$-3,799,000	$3,298,000	$20,777,175	$19,526,967
Invested Capital	$-3,799,000	$3,298,000	$20,777,175	$19,526,967
Working Capital	$743,000	$7,551,000	$25,581,185	$23,385,647
Capital Lease Obligations	$563,000	$761,000	$318,860	$274,831
Total Capitalization	$-3,799,000	$3,298,000	$20,777,175	$19,526,967
Additional Paid In Capital	$419,471,000	$397,673,000	$31,747,324	$29,510,021
Capital Stock	$0	$0	$324,819,840	$297,701,149
Common Stock	$0	$0	$324,819,840	$297,701,149
Non Current Deferred Revenue	$4,910,000	$4,677,000	$5,073,119	$4,958,739
Long Term Capital Lease Obligation	$370,000	$561,000	$218,604	$115,679
Current Capital Lease Obligation	$193,000	$200,000	$100,256	$159,151
Current Accrued Expenses	$2,327,000	$2,574,000	$1,876,979	$1,030,062
Net PPE	$738,000	$985,000	$487,713	$480,401
Accumulated Depreciation	$-526,000	$-439,000	$-523,896	$-452,402
Gross PPE	$1,264,000	$1,424,000	$1,011,609	$932,803
Leases	$644,000	$827,000	$449,269	$388,299
Machinery Furniture Equipment	$620,000	$597,000	$515,604	$498,821
Properties	$0	$0	$0	$0
Other Properties	-	$3,000	$46,736	$45,682
Treasury Shares Number	-	-	$0	-
Other Short Term Investments	-	-	$0	$15,083,996

Fetched: 2026-06-18

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-20,118,000	$-20,057,000	$-21,450,324	$-17,248,747
Operating Activities
Operating Cash Flow	$-20,112,000	$-19,883,000	$-21,444,294	$-17,208,223
Cash Flow From Continuing Operating Activities	$-20,112,000	$-19,883,000	$-21,444,294	$-17,208,223
Operating Gains Losses	$98,000	$-1,978,000	$-3,771,295	$-1,182,582
Investing Activities
Capital Expenditure	$-6,000	$-174,000	$-6,030	$-40,525
Investing Cash Flow	$-6,000	$-174,000	$15,243,480	$-15,033,156
Cash Flow From Continuing Investing Activities	$-6,000	$-174,000	$15,243,480	$-15,033,156
Financing Activities
Issuance Of Capital Stock	$11,767,000	$4,981,000	$23,835,369	$9,264,663
Financing Cash Flow	$14,120,000	$5,028,000	$24,117,292	$8,992,779
Cash Flow From Continuing Financing Activities	$14,120,000	$5,028,000	$24,117,292	$8,992,779
Net Other Financing Charges	$-27,000	-	-	-
Net Common Stock Issuance	$11,767,000	$4,981,000	$23,835,369	$9,264,663
Common Stock Issuance	$11,767,000	$4,981,000	$23,835,369	$9,264,663
Other
End Cash Position	$5,202,000	$11,079,000	$26,316,900	$8,595,638
Beginning Cash Position	$11,079,000	$26,397,000	$8,793,909	$30,402,299
Effect Of Exchange Rate Changes	$121,000	$-289,000	$-393,487	$1,441,939
Changes In Cash	$-5,998,000	$-15,029,000	$17,916,478	$-23,248,600
Proceeds From Stock Option Exercised	$2,380,000	$47,000	$588,723	$8,842
Net PPE Purchase And Sale	$-6,000	$-174,000	$-6,030	$-40,525
Purchase Of PPE	$-6,000	$-174,000	$-6,030	$-40,525
Change In Working Capital	$1,180,000	$2,523,000	$1,330,469	$288,093
Change In Other Working Capital	$-1,682,000	$936,000	$171,868	$-12,526
Change In Other Current Liabilities	$-293,000	$-253,000	$250,264	$-259,358
Change In Payables And Accrued Expense	$-360,000	$884,000	$-58,797	$1,224,580
Change In Accrued Expense	$-360,000	$884,000	-	-
Change In Prepaid Assets	$580,000	$991,000	$585,708	$-918,803
Change In Receivables	$2,935,000	$-35,000	$381,426	$254,200
Changes In Account Receivables	$2,932,000	$4,000	-	-
Other Non Cash Items	$4,195,000	$297,000	$53,520	$-55,998
Stock Based Compensation	$3,104,000	$1,982,000	$1,558,872	$1,752,137
Depreciation Amortization Depletion	$70,000	$87,000	$303,784	$288,830
Depreciation And Amortization	$70,000	$87,000	$303,784	$288,830
Depreciation	$70,000	$87,000	$303,784	$288,830
Gain Loss On Investment Securities	$235,000	$-1,169,000	$-3,983,869	$14,736
Net Foreign Currency Exchange Gain Loss	$-137,000	$-809,000	$212,573	$-1,197,318
Net Income From Continuing Operations	$-28,759,000	$-22,794,000	$-20,919,644	$-18,298,703
Repayment Of Debt	-	$-242,477	$-306,799	$-280,725
Income Tax Paid Supplemental Data	-	$128,206	$90,457	$33,893
Net Issuance Payments Of Debt	-	$-242,477	$-306,799	$-280,725
Net Long Term Debt Issuance	-	$-242,477	$-306,799	$-280,725
Long Term Debt Payments	-	$-242,477	$-306,799	$-280,725
Net Investment Purchase And Sale	-	$0	$15,249,510	$-14,992,632
Sale Of Investment	-	$0	$15,249,510	$0
Purchase Of Investment	-	$0	$0	$-14,992,632

Fetched: 2026-06-18